Acute kidney injury (AKI) is a word that refers to a loss of renal function that occurs suddenly and accompanied with an elevated creatinine levels in the blood (a renal sign) and decreased urinary output (oliguria) (a quantitative metric of urine production), with a 7-day limit. Risk factors for AKI include environmental, socioeconomic and/or cultural factors, as well as factors related to the process of care, acute exposures and patients themselves. Since Stem cell has immense potential in regenerative cellular therapy. Mesenchymal stem cells (MSCs) can become a potential attractive candidate for therapy due to its remarkable ability of self-renewal and differentiation into three lineages, i.e., ectoderm, mesoderm, and endoderm. Stem cell holds tremendous promises in the field of tissue regeneration and transplantation for disease treatments. The project aimed to evaluate the role of bone marrow-mesenchymal stem cells (BM-MCSs) as an anti-inflammatory, anti-oxidant agent and therapy for amikacin (AMK) - induced kidney injury. MSCs transplantation succeeded in amolerated the amikacine-induced nephrotoxicity in balb/c mice. MSCs exerted an antioxidant and anti-inflammatory effects during treatment, where MSCs decreased cytokines levels and elevated the antioxidant enzyme levels in kidney tissue homogenates